Volume | 87,579 |
|
|||||
News | - | ||||||
Day High | 0.3131 | Low High |
|||||
Day Low | 0.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GRI Bio Inc | GRI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3015 | 0.30 | 0.3131 | 0.302 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
91 | 87,579 | $ 0.3037752 | $ 26,604 | - | 0.2882 - 47.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:05:17 | 100 | $ 0.3131 | USD |
GRI Bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 1.18M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GRI Bio News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GRI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.33 | 0.339 | 0.291 | 0.3210117 | 345,331 | -0.0169 | -5.12% |
1 Month | 0.4093 | 0.4798 | 0.2882 | 0.3967487 | 549,373 | -0.0962 | -23.50% |
3 Months | 0.90 | 0.915 | 0.2882 | 0.4783507 | 277,375 | -0.5869 | -65.21% |
6 Months | 4.6151 | 8.1788 | 0.2882 | 1.67 | 568,392 | -4.30 | -93.22% |
1 Year | 42.00 | 47.95 | 0.2882 | 3.25 | 381,502 | -41.69 | -99.25% |
3 Years | 92.40 | 93.31 | 0.2882 | 3.83 | 347,204 | -92.09 | -99.66% |
5 Years | 92.40 | 93.31 | 0.2882 | 3.83 | 347,204 | -92.09 | -99.66% |
GRI Bio Description
GRI Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company¿s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need. |